Gamma scintigraphy was carried out to confirm the development of sustained release depot at the site of injection following the administration of liquid ZP-LPS formulation. Briefly, ZP was radiolabeled with 99mTechnetium-pertechnetate (Tc-99M) by an in-house developed standard procedure using stannous chloride as reducing agent. Labeling efficiency and stability was confirmed by instant thin layer chromatography.16 (link) ZP-LPS Formulation was then developed using Tc-99M labeled ZP. ZP-LPS formulation (0.3 mL) containing 60 μCi ofTc-99Mwas then injected subcutaneously at the back of the three Sprague-Dawley rats. At pre-designated time points, 15 min, 6 h and 12 h, gamma images were captured by gamma camera (Siemens T2 SPECT-CT) to understand drug release and depot formation.17 (link)